Glenmark Pharmaceuticals Limited (BOM:532296)
India · Delayed Price · Currency is INR 2,099.00
-29.20 (-1.37%)
At close: Sep 15, 2025
Glenmark Pharmaceuticals Revenue
Glenmark Pharmaceuticals had revenue of 32.64B INR in the quarter ending June 30, 2025, with 0.62% growth. This brings the company's revenue in the last twelve months to 134.56B, up 4.62% year-over-year. In the fiscal year ending March 31, 2025, Glenmark Pharmaceuticals had annual revenue of 133.63B with 5.68% growth.
Revenue (ttm)
134.56B
Revenue Growth
+4.62%
P/S Ratio
4.37
Revenue / Employee
8.52M
Employees
15,800
Market Cap
588.45B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 133.63B | 7.18B | 5.68% |
| Mar 31, 2024 | 126.45B | 9.90B | 8.49% |
| Mar 31, 2023 | 116.56B | -6.49B | -5.28% |
| Mar 31, 2022 | 123.05B | 13.61B | 12.44% |
| Mar 31, 2021 | 109.44B | 2.87B | 2.69% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Reliance Industries | 9,765.41B |
| HDFC Bank | 2,736.06B |
| Bharti Airtel | 1,839.41B |
| Tata Consultancy Services | 2,561.48B |
| ICICI Bank | 2,054.85B |
| State Bank of India | 3,503.84B |
| Infosys | 1,672.76B |
| Bajaj Finance | 387.76B |
Glenmark Pharmaceuticals News
- 10 days ago - Glenmark Pharma shares jump over 2% after its subsidiary gets $700 million from AbbVie for licensing deal - Business Upturn
- 10 days ago - Glenmark Pharma receives $700 million upfront payment from AbbVie for global licensing deal - Business Upturn
- 14 days ago - Glenmark Pharma initiates multi-country Phase 3 Clinical Trial for Envafolimab in Stage III NSCLC - Business Upturn
- 15 days ago - Bajaj Electricals, UBL& more: Top stocks on brokers' radar today - The Times of India
- 16 days ago - Glenmark Pharma shares jump over 2% as HSBC maintains ‘Buy’ rating with target price of Rs 2,380 - Business Upturn
- 16 days ago - Glenmark Pharma share: HSBC maintains buy with Rs 2,380 target, highlights catalysts in debt reduction and FDA approvals - Business Upturn
- 16 days ago - Stocks to watch on brokerages today, September 3: ITC, Adani Power, Indus Towers, UBL, Glenmark Pharma and more - Business Upturn
- 17 days ago - Glenmark Pharma to launch Eribulin Mesylate Injection in the US market - Business Upturn